Abstract 160P
Background
Nano-liposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard treatment for advanced pancreatic cancer after gemcitabine-based chemotherapy. However, there are limited clinical data on its efficacy and safety. We therefore initiated the NAPOLEON-2 study. Imajima et al. have reported the final results of the retrospective portion of the study (ASCO GI, 2023). Here, we report on the pre-planned interim analysis of the prospective portion, focusing on safety.
Methods
This study is an ongoing multicenter observational study that took place in June 2021, with a target number of 150 cases. The primary endpoint was overall survival, with secondary endpoints including response rate, disease control rate, progression-free survival, dose intensity, and adverse events (AEs). According to the protocol regulation, an interim analysis was conducted once reaching half the number of target cases to verify the validity of further enrollment.
Results
The median follow-up period was 5.3 months. The median age was 71 years (range, 45–83), and the study included seven locally advanced cancer cases. Liver (43), peritoneum (28), and lung (21) were the most common metastatic sites. NFF was administered as a 2nd/3rd/4th- or later-line therapy to 44/25/6 cases, respectively. All patients had previously received gemcitabine-based therapy. For the initial dose, nano-liposomal irinotecan (NAL-IRI) or fluorouracil (FU) was reduced in 41 and 26 cases, respectively, mainly because of organ function (17%) and age (15%). Grade 3/4 hematological or non-hematological AEs occurred in 24 and 29 cases, respectively. Frequently observed grade 3/4 AEs were neutropenia (26%) and anorexia (16%). The median relative dose intensity was 71.5% for NAL-IRI and 82.9% for FU. Dose reduction during treatment was observed in 35 cases with NAL-IRI and 34 cases with FU, mainly from neutropenia (19%) and anorexia (13%).
Conclusions
These results reproduced the retrospective portion in the safety of NFF, validating this interim analysis. NFF was safely administered in practical clinical settings, so we determined that enrollment should be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract